MedPath

Dronabinol

Generic Name
Dronabinol
Brand Names
Marinol, Sativex, Syndros
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
1972-08-3
Unique Ingredient Identifier
7J8897W37S
Background

Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or Nabilone), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

Indication

Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions
Anorexia, Chemotherapy-Induced Nausea and Vomiting

Use of Cannabinoids in Patients With Multiple Sclerosis

Phase 2
Conditions
Multiple Sclerosis
First Posted Date
2005-09-20
Last Posted Date
2005-11-29
Lead Sponsor
S. Andrea Hospital
Target Recruit Count
20
Registration Number
NCT00202423
Locations
🇮🇹

Department of Neurology- University of Rome la Sapienza, Rome, Italy

Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain

Phase 2
Completed
Conditions
Chronic Pain
First Posted Date
2005-09-12
Last Posted Date
2013-04-26
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
30
Registration Number
NCT00153192
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

Phase 2
Completed
Conditions
Migraine With Aura
Migraine Without Aura
First Posted Date
2005-07-22
Last Posted Date
2015-01-16
Lead Sponsor
Solvay Pharmaceuticals
Registration Number
NCT00123201
Locations
🇺🇸

Site 1, Chicago, Illinois, United States

🇺🇸

Site 2, Boston, Massachusetts, United States

🇺🇸

Site 7, St. Petersburg, Florida, United States

and more 26 locations

Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2004-03-10
Last Posted Date
2017-01-11
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
30
Registration Number
NCT00079560
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

Phase 1
Completed
Conditions
Cachexia
HIV Infections
HIV Wasting Syndrome
First Posted Date
2001-08-31
Last Posted Date
2008-08-25
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
56
Registration Number
NCT00000737
Locations
🇺🇸

Denver Public Health Dept, Denver, Colorado, United States

🇺🇸

Univ of Illinois, Chicago, Illinois, United States

🇺🇸

Univ of Kansas School of Medicine, Wichita, Kansas, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath